| Identification | Back Directory | [Name]
CAY10415 | [CAS]
146062-49-9 | [Synonyms]
CS-1615
CAY10415
MSDC-0160
Mitoglitazone
MSDC-0160(CAY10415)
CAY10415 MSDC-0160
MSDC-0160 (Mitoglitazone
CAY10415 (Mitoglitazone)
MITOGLITAZONE;CAY10415;MSDC 0160
CAY10415;CAY-10415;CAY 10415;MSDC 0160;MSDC0160
5-(4-(2-(5-Ethylpyridin-2-yl)-2-oxoethoxy)-benzyl)thiazolidine-2,4-dione
5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-2,4-Thiazolidinedione
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-
5-[[4-[2-(5-ethylpyridin-2-yl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | [EINECS(EC#)]
202-303-5 | [Molecular Formula]
C19H18N2O4S | [MDL Number]
MFCD00916084 | [MOL File]
146062-49-9.mol | [Molecular Weight]
370.43 |
| Chemical Properties | Back Directory | [Boiling point ]
623.8±55.0 °C(Predicted) | [density ]
1.315±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
≥37 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
A crystalline solid | [pka]
6.32±0.50(Predicted) | [color ]
white to beige | [InChI]
1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24) | [InChIKey]
IRNJSRAGRIZIHD-UHFFFAOYSA-N | [SMILES]
CCC1=CN=C(C(COC2=CC=C(CC3SC(NC3=O)=O)C=C2)=O)C=C1 |
| Hazard Information | Back Directory | [Uses]
CAY10415 is used to study blood glucose levels and rates of insulin-stimulated lipogenesis. | [Definition]
ChEBI: 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]thiazolidine-2,4-dione is an aromatic ether. | [Biological Activity]
msdc-0160 is a prototype mtot-modulating insulin sensitizer [1].msdc-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator–activated receptor-γ (ppar-γ)-dependent side effects. co-incubation of islets with msdc-0160 and igf-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. msdc-0160 at 50μm alone also prevents the loss of insulin content significantly. besides that, treatment of msdc-0160 increases the phosphorylation of ampk and reduces mtor phosphorylation. moreover, msdc-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. in addition, msdc-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells [1]. | [in vivo]
MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice[2].
| Animal Model: | Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g[2] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage; daily; for 7 days | | Result: | Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.
|
| [References]
[1] rohatgi n, aly h, marshall c a, et al. novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. plos one, 2013, 8(5): e62012. |
|
|